RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Sees Large Drop in Short Interest

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the recipient of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 107 shares, a drop of 74.8% from the October 15th total of 425 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 660 shares, the short-interest ratio is presently 0.2 days.

RCN Pareto Strategic Allocation ETF Trading Down 0.3%

PRTO traded down $0.08 on Friday, hitting $26.60. 514 shares of the company were exchanged. RCN Pareto Strategic Allocation ETF has a twelve month low of $24.68 and a twelve month high of $28.58. The stock has a market capitalization of $16.95 million, a P/E ratio of -27.71 and a beta of 0.92. The business has a 50-day moving average price of $27.28.

About RCN Pareto Strategic Allocation ETF

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients. One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.